<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> (also called Admantiades-<z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet syndrome</z:e>) is a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The disease is characterized by exacerbations and remissions of symptoms and organ manifestations and may produce only mild mucocutaneous lesions, whereas ocular lesions can cause <z:hpo ids='HP_0000618'>blindness</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In addition, involvement of the gastrointestinal tract, central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) and large blood vessels is sometimes life-threatening </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporin A</z:chebi> is the only agent for treatment of ocular lesions registered in Germany; however, the neurotoxicity and nephrotoxicity restrict usage of the drug </plain></SENT>
<SENT sid="4" pm="."><plain>In patients suffering from severe <z:hpo ids='HP_0000554'>uveitis</z:hpo>, biologics have been a breakthrough </plain></SENT>
<SENT sid="5" pm="."><plain>Interferon (IFN) alpha therapy has shown significant efficacy for intraocular <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Monoclonal antibodies to TNF-alpha and interleukin-1 have been successful in clinical trials and are approved in some countries </plain></SENT>
<SENT sid="7" pm="."><plain>This article summarizes the current state of knowledge and emphasizes the important role of the ophthalmologist in the therapy of <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> </plain></SENT>
</text></document>